Literature DB >> 9125204

Differential effects of a mitogen-activated protein kinase kinase inhibitor on human neutrophil responses to chemotactic factors.

M Kuroki1, J T O'Flaherty.   

Abstract

Chemotactic factors, i.e., an N-formyl peptide, C5a, interleukin-8, and leukotriene B4, induced neutrophils to activate mitogen-activated protein (MAP) kinases, as defined by the tyrosine phosphorylation and decrease in electrophoretic mobility of immunodetected 44-, 42-, and 40-kDa proteins. PD 98059, an inhibitor of MAP kinase kinase activation, blocked these changes. The drug likewise blocked neutrophil chemotaxis but did not alter superoxide anion production and paradoxically enhanced degranulation responses to the stimuli. The MAP kinase pathway appears to have a highly selective role in mediating motility but not other cellular responses.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9125204     DOI: 10.1006/bbrc.1997.6296

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  14 in total

1.  A single amino acid substitution (N297A) in the conserved NPXXY sequence of the human N-formyl peptide receptor results in inhibition of desensitization and endocytosis, and a dose-dependent shift in p42/44 mitogen-activated protein kinase activation and chemotaxis.

Authors:  J M Gripentrog; A J Jesaitis; H M Miettinen
Journal:  Biochem J       Date:  2000-12-01       Impact factor: 3.857

2.  'Outside-in' signalling mechanisms underlying CD11b/CD18-mediated NADPH oxidase activation in human adherent blood eosinophils.

Authors:  O T Lynch; M A Giembycz; P J Barnes; P G Hellewell; M A Lindsay
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

3.  Inhibition of IL-8-mediated MAPK activation in human neutrophils by beta1 integrin ligands.

Authors:  Demetra Xythalis; Mary Beth Frewin; Paul W Gudewicz
Journal:  Inflammation       Date:  2002-04       Impact factor: 4.092

4.  Threshold levels of ERK activation for chemotactic migration differ for NGF and EGF in rat pheochromocytoma PC12 cells.

Authors:  W C Ho; S Uniyal; H Zhou; V L Morris; B M C Chan
Journal:  Mol Cell Biochem       Date:  2005-03       Impact factor: 3.396

5.  Artocarpol A stimulation of superoxide anion generation in neutrophils involved the activation of PLC, PKC and p38 mitogen-activated PK signaling pathways.

Authors:  Yu-Hsiang Kuan; Ruey-Hseng Lin; Lo-Ti Tsao; Chun-Nan Lin; Jih-Pyang Wang
Journal:  Br J Pharmacol       Date:  2005-06       Impact factor: 8.739

6.  Protective effects of luteolin against lipopolysaccharide-induced acute lung injury involves inhibition of MEK/ERK and PI3K/Akt pathways in neutrophils.

Authors:  Jen-pei Lee; Yi-ching Li; Hung-yi Chen; Ruey-hseng Lin; Shiang-suo Huang; Hui-ling Chen; Pai-chuan Kuan; Mao-fang Liao; Chun-jung Chen; Yu-hsiang Kuan
Journal:  Acta Pharmacol Sin       Date:  2010-06-21       Impact factor: 6.150

7.  Differential regulation of neutrophil chemotaxis to IL-8 and fMLP by GM-CSF: lack of direct effect of oestradiol.

Authors:  Li Shen; Jennifer M Smith; Zheng Shen; Stephen B Hussey; Charles R Wira; Michael W Fanger
Journal:  Immunology       Date:  2006-02       Impact factor: 7.397

8.  Extracellular signal-regulated protein kinase (ERK)-dependent and ERK-independent pathways target STAT3 on serine-727 in human neutrophils stimulated by chemotactic factors and cytokines.

Authors:  M Kuroki; J T O'Flaherty
Journal:  Biochem J       Date:  1999-08-01       Impact factor: 3.857

9.  Phospholipase A2-mediated activation of mitogen-activated protein kinase by angiotensin II.

Authors:  N O Dulin; L D Alexander; S Harwalkar; J R Falck; J G Douglas
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

10.  Neutrophils stimulated with a variety of chemoattractants exhibit rapid activation of p21-activated kinases (Paks): separate signals are required for activation and inactivation of paks.

Authors:  R Huang; J P Lian; D Robinson; J A Badwey
Journal:  Mol Cell Biol       Date:  1998-12       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.